Evidence map›Paper›PMID 39636099›Full record

ArticleACS chemical neuroscience2024

Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-

Grant C Glatfelter, Allison A Clark, Natalie G Cavalco, Antonio Landavazo, John S Partilla, Marilyn Naeem, James A Golen, Andrew R Chadeayne, David R Manke, Bruce E Blough and 2 more

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Biased Signaling in Psychedelic Action.Annual review of pharmacology and toxicology · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Grant C GlatfelterDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.ORCID 0000-0003-1011-9083
Allison A ClarkDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
Natalie G CavalcoDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
Antonio LandavazoCenter for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States.
John S PartillaDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.
Marilyn NaeemDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
James A GolenDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
Andrew R ChadeayneDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
David R MankeDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.ORCID 0000-0002-2513-4801
Bruce E BloughCenter for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States.
John D McCorvyDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
Michael H BaumannDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.ORCID 0000-0001-7758-1470

Funding

Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
POTENTIAL TREATMENT MEDICATIONS FOR DRUG ABUSER01DA012970 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI BLOUGH, BRUCE E · 1999 to 2013
$5.5M
Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic PotentialR01MH133849 · NIMH · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2023 to 2026
$2.1M
Development of Dual Dopamine/Serotonin Releasing AgentsZ01DA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$598k
Intramural NIH HHS Z01 DA000522Intramural NIH HHS ZIA DA000522NIDA NIH HHS R01 DA012970NIMH NIH HHS R01 MH133849
6 · The paper itself

Abstract

5-methoxy-

Indexed as

Receptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2AAnimalsBehavior, AnimalHallucinogensHead MovementsHumansMaleMethoxydimethyltryptaminesMiceMice, Inbred C57BLHallucinogensMethoxydimethyltryptaminesReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2A5-HT1A5-HT2A5-MeO-DMThead twitch responsemicetryptamines

Identifiers

PMID39636099
PMCPMC12745965

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.